PTH(1-34) for surgical hypoparathyroidism: A prospective, open-label investigation of efficacy and quality of life

Abstract

Context: Conventional therapy for hypoparathyroidism consists of calcium and calcitriol, but sometimes normal serum calcium cannot be maintained, and/or this approach might lead to nephrocalcinosis, nephrolithiasis, or renal insufficiency. Objective: The objective of the study was to investigate the effects of 6 months of PTH(1-34) treatment in adult subjects with postoperative hypoparathyroidism and to evaluate quality-of-life changes. Design: This was a 2-year prospective, open-label study. At baseline and after 6 months of PTH(1-34) treatment, calcium and Vitamin D supplementation requirements, serum calcium, phosphate, creatinine, alkaline phosphatase, uric acid, and 24-hour urinary calcium excretion were evaluated. Quality of life was evaluated by the Rand 36-Item Short Form Health Survey covering eight domains of physical and mental health. Setting: This was an Italian multicentric study. Participants: Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y). Intervention: The intervention included a twice-daily PTH(1-34) 20 μg sc injection. Results: The mean serum calcium levels significantly increased from baseline to 15 days (7.6 ± 0.6 vs 9.1±0.9 mg/dL, P < .001). Data from the Rand 36-Item Short Form Health Survey showed a significant improvement in the mean scores of all eight domains (P < .001). Conclusion: This is the largest study that demonstrates the effectiveness of PTH(1-34) in the treatment of adult patients with postsurgical hypoparathyroidism, and it shows that PTH(1-34) may improve the mental and physical health in hypoparathyroid subjects.